• Angiotech Pharmaceuticals announced a licensing deal with Baxter for COSEAL, Angiotech’s surgical sealant; Baxter pays $25M [PR Newswire]

• Shire Pharmaceuticals and GSK will team up to promote Vyvanse in the US. [WSJ]

• Wyeth submits marketing application to FDA for its 13-valent vaccine for the prevention of pneumococcal disease in infants and toddlers. [Reuters]

• Takeda Pharmaceuticals moving its R&D facilities to Chicago; creates jobs. [Los Angeles Times]

• Astra’s Recentin may rival Roche’s Avastin. [The Post Chronicle]

• GSK resubmits HPV vaccine, Cervarix, BLA. [PharmaTimes]

ACC Roundup Part 2

• 5-in-1 PolyPill may be next big thing for cardiovascular health. [BBC]

• BMS’s Plavix reduces stroke risk. [Bloomberg]

• Omega-3’s don’t improve overall survival in heart attack patients . [USNews]

• Interim phase 3 data for NicOx’ naproxcinod; focus on reduction of systolic blood pressure. [FoxBusiness]

Image from monster

Related Posts